First AREDS 2 AMD product hits market

Article

Visual Advantage by Macular Health is the first product available to the public featuring the new AREDS 2 formula for preventing vision loss due to AMD.

 

Birmingham, AL-Visual Advantage by Macular Health has become the first product available to the public featuring the new AREDS 2 formula for preventing vision loss due to AMD.

Macular Health's original supplement formulation was modeled after the results of AREDS I, released in 2001. However, Jeffery McAnnally, president and chief executive officer of Macular Health, along with John O. Mason, III, MD, a retina surgeon from the University of Alabama at Birmingham Callahan Eye Foundation Hospital, modified the formula slightly to include lutein and zeaxanthin, which were ultimately proven by AREDS 2 to be the keys to the supplement's effectiveness.

Macular Health's Visual Advantage is specially formulated in the United States by an FDA inspected and GMP (Good Manufacturing Practices) compliant facility.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
© 2025 MJH Life Sciences

All rights reserved.